Case report: persistent anemia after eculizumab in paroxysmal nocturnal hemoglobinuria: non-dominantly active intravascular hemolysis.

Hemoglobinuria-associated acute kidney injury in hemolytic uremic syndrome without renal thrombotic microangiopathy.

Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment.

Decrease in PNH-type Blood Cells after the Cessation of Thrombopoietin Receptor Agonist in a Case of AA-PNH Syndrome.

[Efficacy and safety of romiplostim N01 for refractory aplastic anemia: a retrospective single-center study].

Thrombosis in paroxysmal nocturnal hemoglobinuria in the complement inhibitor era: mechanisms, risk stratification, and clinical management.

Renal hemosiderosis in paroxysmal nocturnal hemoglobinuria.

Analysis of adverse drug reactions associated with ravulizumab: a retrospective pharmacovigilance study utilizing the FAERS database.

Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide in Patients With Large Paroxysmal Nocturnal Hemoglobinuria Clones.

A Prospective 1-Year Study of Renal Recovery in Pigment Nephropathy: Insights Beyond the Acute Phase.

Paroxysmal Nocturnal Hemoglobinuria as a Rare Cause of Chronic Asymptomatic Hemolysis: A Case Report.

The Challenges Associated with the Diagnosis and Treatment for Aplastic Anemia Concurrent with Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia.

Optimizing Care in Patients with Paroxysmal Nocturnal Hemoglobinuria: Managing Suboptimal Response and Uncontrolled Disease.

Real-World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry.

Hematologic disorders in pregnancy: the role of the complement system.

Zilucoplan is effective for ravulizumab-refractory generalized myasthenia gravis with the C5 p.Arg885His variant: a case report.

Population PK-PD Modeling of Danicopan Add-On Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria Treated With Ravulizumab or Eculizumab.

Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 Inhibitors.

COEXISTENCE OF APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: DIAGNOSTIC CHALLENGES AND THERAPEUTIC STRATEGIES - CASE REPORT.

Disease burden and treatment patterns of paroxysmal nocturnal hemoglobinuria in Japan: a real-world survey.

[How I diagnose and treat paroxysmal nocturnal hemoglobinuria].

Paroxysmal Nocturnal Hemoglobinuria in a Young Adult Woman: A Representative Case of Recurrent Intravascular Hemolysis.

Switching patients with PNH from pegcetacoplan to iptacopan: a case series.

Clonal expansion mechanisms in paroxysmal nocturnal hemoglobinuria.

Complement Biomarkers for Monitoring Last-Generation Complement Inhibitors in Paroxysmal Nocturnal Hemoglobinuria Patients.

Ravulizumab for Treatment of Paroxysmal Nocturnal Hemoglobinuria During Pregnancy.

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria.

Integrative miRNA-mRNA Network and Molecular Dynamics-Based Identification of Therapeutic Candidates for Paroxysmal Nocturnal Hemoglobinuria.

Psychometric performance of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue questionnaire among adults with paroxysmal nocturnal hemoglobinuria.

Tailoring Eculizumab Treatment: Evaluation of Model-Informed Precision Dosing for Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome.

Real life use of ravulizumab in Italian patients with paroxysmal nocturnal hemoglobinuria: evidence from the REACTION observational study.

Acute kidney injury as a harbinger of paroxysmal nocturnal hemoglobinuria in an unsuspected case.

[Advancing treatment goals for paroxysmal nocturnal hemoglobinuria to align with quality of life improvements in the era of anti-complement therapy].

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making.

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Discovery of (3R,4R)-15: An Advanced Factor B Inhibitor Entering Phase 3 for Complement-Mediated Diseases.

[Targeting complement in atypical hemolytic and uremic syndrome: development and current status of eculizumab and ravulizumab].

Lyme disease as a rare trigger for autoimmune hemolytic anemia.

Laboratory findings in patients treated with complement factor C3 inhibitor pegcetacoplan.

Disease-modifying treatments in paroxysmal nocturnal hemoglobinuria: a systematic review of economic evaluations.

Paroxysmal Nocturnal Hemoglobinuria-Driven Hepatic Vein Thrombosis: A Case of Budd-Chiari Syndrome in Disguise.

Paroxysmal nocturnal hemoglobinuria presenting with acute kidney injury in an 18-year-old male: a case report.

Whole genome sequencing confirms reactivation of Tuberculosis five years after initial infection despite adequate preventative therapy in a patient with profound immunosuppression.

[Current Perspectives on Paroxysmal Nocturnal Hemoglobinuria (PNH)].

Pathophysiology of Primary Budd-Chiari Syndrome: A Narrative Review.

Successful Birth After First-Trimester Ravulizumab Exposure in a Patient With Paroxysmal Nocturnal Hemoglobinuria: A Case Report.

First report of perioperative iptacopan interruption in paroxysmal nocturnal hemoglobinuria without breakthrough hemolysis.

C3 mutations and poor pegcetacoplan response in paroxysmal nocturnal hemoglobinuria.

[The night has many faces: When schistocytes step out of line].

Free GPIs and Comparison of GPI Structures Among Species.

A rare case of littoral cell angioma with paroxysmal nocturnal hemoglobinuria.

Thrombin generation in PNH patients treated sequentially with Eculizumab and Ravulizumab: a paired analysis.

The varieties of therapeutic experience: navigating treatment options for patients with PNH.

Rotational Thromboelastometry (ROTEM)-Assisted Anaesthetic Management of a Parturient With Paroxysmal Nocturnal Haemoglobinuria and Aplastic Anaemia for Caesarean Section: A Case Report.

Complement factor D is a drug target for metabolic-associated fatty liver disease.

Myeloproliferative neoplasms with clinically relevant paroxysmal nocturnal hemoglobinuria: clinical correlations and outcomes.

Efficacy and Safety of the C5 Inhibitor Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.

Predicting secondary myeloid neoplasms in acquired aplastic anemia using machine learning models.

Diffuse Large B-Cell Lymphoma Combined With Paroxysmal Nocturnal Hemoglobinuria: A Rare Case Report.

Paroxysmal Nocturnal Hemoglobinuria in Pregnancy Treated With Pegcetacoplan: Case Report and Pharmacokinetic Analysis.

Advances in Complement Inhibition Therapies for Paroxysmal Nocturnal Hemoglobinuria and Autoimmune Hemolytic Disorders.

A case of allogeneic peripheral blood stem cell in a paroxysmal nocturnal hemoglobinuria patient from a COVID-positive donor: Managing the unpreventable.

Common features of rare disease patients in the emergency department: a systematised literature review.

Hepatic Sinusoidal Obstruction Syndrome Secondary to Aplastic Anemia/Paroxysmal Nocturnal Hemoglobinuria Syndrome: A Rare Case.

Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria.

Long-term outcomes of αβ T-cell/CD19 B-cell-depleted peripheral blood stem cell transplantation from unrelated donors in pediatric and adolescent patients with severe aplastic anemia: a single-center study.

Paroxysmal Nocturnal Hemoglobinuria.

Complement-targeting therapies in hemolytic diseases.

Consensus of the Hematology Society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH).

Improved Iron Overload with Pegcetacoplan in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria.

[Significance of the 50% hemolytic complement in hemolysis assessment and efficacy of eculizumab in patients with paroxysmal nocturnal hemoglobinuria].

Iptacopan in C5 blockade refractory atypical hemolytic uremic syndrome with associated Castleman's disease: case report.

Paroxysmal Nocturnal Hemoglobinuria in Patients with Systemic Lupus Erythematosus: Diagnostic Challenges and Improvement with C5 Inhibitor Treatment.

Efficacy and safety of vemircopan as monotherapy in patients with paroxysmal nocturnal hemoglobinuria.

Case report: Spontaneous remission of severe aplastic anemia mediated by mutant hematopoietic stem cells evading T-cell attack.

Identification of plasma protein biomarkers for ankylosing spondylitis by integrating proteome with genome.

Progress in the use of biological therapies to treat paroxysmal nocturnal hemoglobinuria: focus on patient profiling.

Ravulizumab exposure in early pregnancy.

Repair of Congenital Cardiac Disease Requiring Bypass for a Pediatric Patient With Paroxysmal Nocturnal Hemoglobinuria.

Correlation of clone size with clinical and lab presentation in Paroxysmal nocturnal hemoglobinuria (PNH): A single center experience.

Paroxysmal nocturnal hemoglobinuria revealed by atypical thromboses: A case of cerebral, hepatic, and portal vein involvement leading to cirrhosis.

First reported case of Moraxella lacunata bacteremia following pharyngitis in an adult with paroxysmal nocturnal hemoglobinemia receiving ravulizumab: A case report.

[Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape].

Paroxysmal Nocturnal Hemoglobinuria: Unraveling Its Molecular Pathogenesis and Advancing Targeted Therapeutic Strategies.

Biosynthesis of GPI anchored proteins, its deficiencies and treatment.

Structure and function of therapeutic antibodies approved by the US FDA in 2024.

Telomere content and genomics of myeloid neoplasia by whole-genome sequencing.

Managing transient immune complex reactions in patients with paroxysmal nocturnal hemoglobinuria: clinical observations from the COMMODORE 1 and 2 studies.

Successful switch from pegcetacoplan to iptacopan after repeated severe breakthrough hemolysis events - case report.

[Diagnosis of non-autoimmune hemolysis in the adult].

Paroxysmal Nocturnal Hemoglobinuria Associated Cutaneous Thrombosis: A Case Report.

Paroxysmal Nocturnal Hemoglobinuria with Large Clones in Non-Hypoplastic Myelodysplastic Syndrome: Report of Two Cases.

Enigmatic Roles of Complement Anaphylatoxin Signaling in Health and Disease.

[New treatment strategies for paroxysmal nocturnal hemoglobinuria: drug selection in the era of novel complement inhibitors].

Clinical characteristics and management of paroxysmal nocturnal hemoglobinuria in the Middle East: a narrative review.

Viral infections and related fatal adverse events associated with complement inhibitors for PNH: a real-world pharmacovigilance analysis in FAERS.

PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.

Case Report: Iptacopan in a paroxysmal nocturnal hemoglobinuria patient with severe renal insufficiency.

Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis.

Successful Control of Chemotherapy-Induced Breakthrough Hemolysis With Ravulizumab in a Patient With Paroxysmal Nocturnal Hemoglobinuria During Carboplatin-Pemetrexed Treatment for Lung Adenocarcinoma.

Paroxysmal nocturnal hemoglobinuria masquerading as hemolytic uremic syndrome: a Case Report.

Danicopan: complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.

Characterization of Breakthrough Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria: An International Multicenter Experience.

Disseminated gonococcal infection developing two days after initial eculizumab administration in a patient with neuromyelitis optica spectrum disorder: A case report and literature review.

The Onerous task of managing paroxysmal nocturnal hemoglobinuria in a Low resource setting: a case report. A hematologist's experience.

Targeting the Roots of Kidney Disease: Systematic Review of the Therapies Targeting the Complement System.

Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.

Safety, Efficacy, and Patient-Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria.

Patient-Reported Meaningful Change in Symptoms and Impacts of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Three Phase III Clinical Trials of Iptacopan.

A decade of acquired aplastic anemia: insights from a Central South African Center.

Treatment burden in patients with paroxysmal nocturnal hemoglobinuria: an in-depth interview survey.

Crovalimab: A Novel Approach in the Management of Paroxysmal Nocturnal Hemoglobinuria.

The incidence of paroxysmal nocturnal hemoglobinuria cell clones in the Nordic countries.

Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary.

Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report.

[Pharmacological characteristics and clinical study results of danicopan (Voydeya® tablets)].

Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape.

Whole blood thrombin generation hypercoagulable profile in a patient with hemolytic crisis due to paroxysmal nocturnal hemoglobinuria: a case report.

The Silent Culprit: Paroxysmal Nocturnal Hemoglobinuria Masquerading as Cryptogenic Stroke.

First-in-Class Clinically Investigated Oral Factor D Inhibitors for the Treatment of Complement-Mediated Diseases.

Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria.

The Silent Masquerader: Paroxysmal Nocturnal Hemoglobinuria Revealed.

[Recent advances in the treatment of paroxystic nocturnal hemoglobinuria].

Red Blood Cells are Critical for Hemostasis and Thrombosis.

Two Cases of Crovalimab-Induced Platelet Recovery in Bone Marrow Failure-Associated Paroxysmal Nocturnal Hemoglobinuria (PNH).

Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.

RBPJ/PAF1 Signaling Axis Promotes Cloning Expansion in Paroxysmal Nocturnal Hemoglobinuria Through NOTCH Signaling.

Direct oral anticoagulants as secondary prophylaxis of venous thromboembolism in paroxysmal nocturnal hemoglobinuria: an Italian monocentric experience.

[A case of paroxysmal nocturnal hemoglobinuria treated with eculizumab in unintended pregnancy].

Efficient production of functional proaerolysin in E. coli.

[Correlation between complement deposition levels on blood cells and clinical biomarkers in patients with paroxysmal nocturnal hemoglobinuria].

Effectiveness of Iptacopan Versus C5 Inhibitors in Complement Inhibitor-Naive Patients With Paroxysmal Nocturnal Haemoglobinuria.

Real-World Evidence of the Disease Burden and Economic Impact of Paroxysmal Nocturnal Hemoglobinuria in Italy.

Design, Synthesis, and Biological Evaluation of a Novel Long-Acting Human Complement C3 Inhibitor Synthesized via the PASylation-Lipidation Modular (PLM) Platform.

[Limitations and challenges of glucocorticoids in the treatment of paroxysmal nocturnal hemoglobinuria].

Advancements in complement inhibition for PNH and primary complement-mediated thrombotic microangiopathy.

[Clinical and Laboratory Characteristics of Cold Agglutinin Disease Patients with Positive Results of Acidified-Serum Lysis Test].

Comparison of monoclonal antibody to CD59 for the diagnosis of paroxysmal nocturnal hemoglobinuria by flow cytometry.

Complement dysregulation at lymphatics.

What are the most important quality of life domains for patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria?

Current view on the etiopathogenesis of aplastic anemia.

Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria.

Dose Adjustments of Pegcetacoplan in a Patient With Paroxysmal Nocturnal Hemoglobinuria Undergoing Surgery: A Case Report.

Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment.

The Advancing Landscape of Paroxysmal Nocturnal Hemoglobinuria Treatment.

Flow Cytometric Bone Marrow Evaluation in Suspected Myelodysplastic Neoplasms.

Red blood cells undergo lytic programmed cell death involving NLRP3.

[Efficacy of iptacopan monotherapy for suboptimal response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria].

Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice.

The efficacy of immunosuppressive therapy with or without thrombopoietin receptor agonist in elderly patients with severe aplastic anemia.

Warren Alpert Medical School of Brown University: Clinicopathologic Conference: September 20th, 2024. A Woman in her 20s with Abdominal Pain, Anemia and Thrombocytopenia.

[Unrelated bone marrow transplantation for acute myeloid leukemia evolved from paroxysmal nocturnal hemoglobinuria].

Short-term recurrent coronary artery thrombosis with acute myocardial infarction in a patient with aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: a case report.

Prevention and Management of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria in Asia: A Narrative Review.

EPYSQLI (SB12; Biosimilar to Reference Eculizumab) in Asian and Non-Asian Patients With Paroxysmal Nocturnal Hemoglobinuria: Subgroup Analysis of a Global Phase III Randomized Controlled Trial.

Crovalimab: a new era in paroxysmal nocturnal hemoglobinuria management.

FDA approval of crovalimab: a milestone in paroxysmal nocturnal hemoglobinuria treatment.

Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database.

Pathogenesis of paroxysmal nocturnal hemoglobinuria.

Somatic mutations in Brazilian patients with paroxysmal nocturnal hemoglobinuria: a comprehensive analysis.

[Advances in complement inhibition therapy for paroxysmal nocturnal hemoglobinuria].

A Rare Cause of Recurrent Abdominal Pain.

Pegcetacoplan for Breakthrough Hemolysis in an Adolescent With Classical Paroxysmal Nocturnal Hemoglobinuria on Eculizumab.

Factor B as a therapeutic target for the treatment of complement-mediated diseases.

Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy.

Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders.

The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome.

Development and application of UHPLC-MS/MS method to quantify eculizumab in PNH patients.

Discovery of a second, distinct development pattern of leukemic conversion from paroxysmal nocturnal hemoglobinuria.

Thrombosis at Unusual Sites: Focus on Myeloproliferative Neoplasms and Paroxysmal Nocturnal Hemoglobinuria.

Direct Oral Anticoagulants and Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Update on Evidence.

Modulating the complement system through epitope-specific inhibition by complement C3 inhibitors.

Unraveling the Mysteries: Paroxysmal Nocturnal Hemoglobinuria and Its Unexpected Link to Stroke in Young Adult.

Eculizumab treatment for Chinese patients with hemolytic paroxysmal nocturnal hemoglobinuria (PNH): efficacy and safety - a single-center study.

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database.

Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.

Current status and perspectives of hematopoietic cell transplantation in patients with paroxysmal nocturnal hemoglobinuria.

More Than a Haematoma: A Case of Aplastic Anemia.

Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.

[Interpretation of the guidelines for diagnosing and treating paroxysmal nocturnal hemoglobinuria in China (2024)].

[Clinical observation of allogeneic hematopoietic stem cell transplantation for treating five cases of classic paroxysmal nocturnal hemoglobinuria].

[Paroxysmal Nocturnal Hemoglobinuria: A Rare but Treatable Cause of Acute Kidney Injury. Case Report].

Proximal complement inhibitors in paroxysmal nocturnal hemoglobinuria: an abundance of options in a rare disease.

Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators.

Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH.

Concurrent Loss of CD16 in Granulocytes and CD14 in Mature Monocytes in a Patient With Pancytopenia: A Diagnostic Clue for Paroxysmal Nocturnal Hemoglobinuria.

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria.

Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH).

Advancements in PNH treatment: crovalimab's clinical efficacy.

An Unusual Case of Relapsing and Remitting Acute Kidney Injury.

Crovalimab in the paroxysmal nocturnal hemoglobinuria treatment landscape.

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Pegcetacoplan in Patients with Paroxysmal Nocturnal Hemoglobinuria.

Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial.

Monitoring and Treatment of Paroxysmal Nocturnal Hemoglobinuria in Patients with Aplastic Anemia in Asia: An Expert Consensus.

Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment.

Fluorescent Aerolysin (FLAER) Binding Is Abnormally Low in the Clonal Precursors of Acute Leukemias, with Binding Particularly Low or Absent in Acute Promyelocytic Leukemia.